Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CheckMate 816 neoadjuvant therapy study in early-stage resectable non-small cell lung cancer
jRCT2080223597Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jul 2017
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial of nivolumab, ipilimumab, carboplatin, cisplatin, gemcitabine and 4 more in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Bristol Myers Squibb. Started Jul 2017; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2080223597.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223597.